New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
13:47 EDTSNY, REGNRegeneron price target raised to $382 from $362 at Roth Capital
Roth Capital raised its price target on Regeneron (REGN) after the company and partner Sanofi (SNY) presented the full data set from the ODYSSEY MONO study, along with data supporting the potential for once per month dosing with alirocumab. Roth noted that Sanofi is guiding to filing for approval for the drug in 2016.
News For REGN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
09:25 EDTREGNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Wendy's (WEN), up 3.5%. ALSO HIGHER: ITC Holdings (ITC), up 1.1% after being acquired by Fortis for in a deal valued at $11.3B... Kinross Gold (KGC), up 2.9% after being upgraded to Outperform from Neutral at Credit Suisse... Boston Scientific (BSX), up 3.1% after announcing that Medicare will cover Watchman left atrial appendage closure Device. DOWN AFTER EARNINGS: Regeneron (REGN), down 7.2%... Twenty-First Century Fox (FOXA, FOX), down 6.7% and 2.6%, respectively... CVS Health (CVS), down 3.5%... Viacom (VIAB), down 3.2%. ALSO LOWER: Constant Contact (CTCT), down 3.3% after Bloomberg reported that Endurance International (EIGI) withdrew a $735M loan Monday that was intended to help fund its $1.1B takeover of the company... Paypal (PYPL), down 2.4% after announcing a Chief Technology Officer transition.
08:08 EDTSNYSanofi sees FY16 business EPS to be broadly stable at CER
Subscribe for More Information
06:33 EDTREGNRegeneron sees FY16 U.S. Eylea revenue up 20% over FY15
06:32 EDTREGNRegeneron reports U.S. Eylea revenue $746M vs. $518M last year
Subscribe for More Information
06:32 EDTREGNRegeneron reports Q4 EPS $2.83, consensus $3.36
Subscribe for More Information
05:28 EDTSNYSanofi reports Q4 business EPS down 5.8% to EUR 1.31
Subscribe for More Information
February 8, 2016
14:28 EDTREGNNotable companies reporting before tomorrow's open
Subscribe for More Information
07:25 EDTREGNBiotech Industry Organization to hold a conference
Subscribe for More Information
06:28 EDTSNYPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
February 5, 2016
09:26 EDTREGNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:06 EDTREGNRegeneron resumed with an Outperform at Leerink
Subscribe for More Information
February 4, 2016
16:37 EDTREGNRegeneron reinitiated with an Outperform at Leerink
Target $534.
February 2, 2016
11:09 EDTSNYSanofi plans to cut 600 jobs in France over three years, Bloomberg reports
Subscribe for More Information
07:24 EDTSNYSanofi, Merck mulling exiting vaccine JV, Bloomberg reports
Subscribe for More Information
05:19 EDTSNYSanofi Pasteur launches R&D project targeting prevention of Zika virus infection
Subscribe for More Information
January 29, 2016
13:38 EDTSNY, REGNAmgen wins right to allege willful infringement in Praluent suit, Markman says
Subscribe for More Information
January 27, 2016
10:00 EDTREGNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BG Group (BRGYY) downgraded to Neutral from Outperform at Credit Suisse... Bed Bath & Beyond (BBBY) downgraded to Sell from Neutral at Citi... Bill Barrett (BBG) downgraded to Neutral from Buy at Ladenburg... Brown & Brown (BRO) downgraded to Underweight at Morgan Stanley... Buffalo Wild Wings (BWLD) downgraded to Neutral from Buy at BTIG... Canadian National (CNI) downgraded to Market Perform from Outperform at Raymond James... DreamWorks (DWA) downgraded to Sell from Hold at Topeka... FirstMerit (FMER) downgraded at RBC Capital... Gentex (GNTX) downgraded to Neutral from Outperform at Baird... Haverty Furniture (HVT) downgraded to Sector Weight from Overweight at KeyBanc... Hercules Technology (HTGC) downgraded to Neutral from Buy at Compass Point... Horizon Technology (HRZN) downgraded to Market Perform from Outperform at Raymond James... Installed Building downgraded to Sector Weight from Overweight at KeyBanc... Jarden (JAH) downgraded to Neutral from Buy at Citi... K+S (KPLUF) downgraded to Sell from Hold at Berenberg... La-Z-Boy (LZB) downgraded at BB&T... Legacy Reserves (LGCY) downgraded to Market Perform from Outperform at FBR Capital... Medivation (MDVN) downgraded to Hold from Buy at Canaccord... Merck (MRK) downgraded to Neutral from Buy at BofA/Merrill... Metaldyne Performance (MPG) downgraded to Neutral from Outperform at Baird... Pier 1 Imports (PIR) downgraded to Sector Weight from Overweight at KeyBanc... Priceline (PCLN) downgraded to Neutral from Buy at Goldman... Profire Energy (PFIE) downgraded to Neutral from Buy at Chardan... Regeneron (REGN) downgraded to Hold at Canaccord... Starwood (HOT) downgraded to Underperform from Outperform at CLSA... Swiss Re (SSREY) downgraded to Equal Weight from Overweight at Morgan Stanley... TSYS (TSS) downgraded to Equal-Weight from Overweight at First Analysis... Talmer Bancorp (TLMR) downgraded to Sector Perform from Outperform at RBC Capital... TopBuild (BLD) downgraded to Sector Weight from Overweight at KeyBanc... TripAdvisor (TRIP) downgraded to Sell from Neutral at Goldman... VMware (VMW) downgraded to Hold from Buy at Summit Research... W.R. Grace (GRA) downgraded to Buy from Conviction Buy at Goldman... WEC Energy (WEC) downgraded to Neutral from Conviction Buy at Goldman... Welltower (HCN) downgraded to Underperform from Market Perform at BMO Capital... Yamana Gold (AUY) downgraded to Neutral from Overweight at JPMorgan.
07:12 EDTREGNRegeneron downgraded to Hold at Canaccord
As reported previously, Canaccord analyst John Newman downgraded Regeneron to Hold from Buy. The analyst anticipates a slowing trajectory for EYLEA as he believes the boost from Protocol-T has largely been realized and price increases are unlikely due to the deep discount offered by off-label Avastin usage. Newman lowered his price target to $525 from $700 on Regeneron shares.
06:57 EDTREGNRegeneron downgraded to Hold from Buy at Canaccord
Subscribe for More Information
January 26, 2016
15:31 EDTSNYMannKind exploring potential sale, Reuters reports
MannKind (MNKD), whose shares have plunged 40% since Sanofi (SNY) terminated an agreement for the development and commercialization of inhaled insulin drug Afrezza, is now exploring its strategic options, including a potential sale, reported Reuters, citing people familiar with the matter. MannKind shares are up about 20% to 90c in afternoon trading following the report. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use